Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg

Healthy male volunteers were randomized into one group among 6 sequential groups and were administered alone or in combination with dapoxetine 30mg mirodenafil 100mg in each period. Bloods were obtained at each time for pharmacokinetic analysis. Safety evaluation was also done during entire study period.

Inclusion criteria

• Healthy male adults aged between 19 and 55
• Body mass index (BMI) in the range of 19 to 27 kg/m2
• Understand the requirements of the study and voluntarily consent to participate in the study
• Available for the entire study period

Exclusion criteria

• Subject has a history such as liver diseases, kidneys, digestive system, respiratory system, endocrine system, nervous psychiatric, blood, cancer, cardiovascular diseases
• Subject with clinically significant vital signs (sitting position blood pressure) (90 mmHg > systolic blood pressure ≥ 140 mmHg, 60 mmHg > diastolic blood pressure ≥ 90 mmHg)
• History of drug abuse
• History of caffeine, alcohol, smoking abuse

• caffeine(coffee,tea,coke)> 4cups/day
• smoking > 10 cigarettes/day
• alcohol > 140g/week
• Consumption of any grapefruit or grapefruit-containing juices over 1 cup a day
• Previously donate whole blood within 60 days or component blood within 30 days
• Subject has taken drugs which affects the ADME of investigational products
• Subject with known for hypersensitivity reactions to mirodenafil/ dapoxetine or other drugs
• Inadequate laboratory test result:

• AST(SGOT) or ALT(SGPT) or total bilirubin > 1.5 x upper limit of normal range
• Subject considered as unsuitable based on medical judgement by investigators